Insulet (PODD) Stock Price, News & Analysis

Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Key Stats

• Today's Range: $300.61 to $305.92
• 50-Day Range: $238.57 to $327.47
• 52-Week Range: $173.00 to $329.33
• Volume: 591,849 shs
• Average Volume: 711,970 shs
• Market Capitalization: $21.42 billion
• P/E Ratio: 54.75
• Dividend Yield: N/A
• Price Target: $321.00
• Consensus Rating: Moderate Buy

Insulet Stock Analysis - MarketRank™

Insulet scored higher than 86% of companies evaluated by MarketBeat, and ranked 275th out of 1,880 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insulet has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 26.79%

Earnings Growth

Earnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insulet is 54.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insulet is 54.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.94.

Price to Earnings Growth Ratio

Insulet has a PEG Ratio of 2.73. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Insulet has a P/B Ratio of 17.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.72% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently decreased by 16.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insulet does not currently pay a dividend.

Dividend Growth

Insulet does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -1.20

Percentage of Shares Shorted

2.72% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insulet has recently decreased by 16.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.90

News Sentiment

Insulet has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Insulet this week, compared to 13 articles on an average week.

Search Interest

Only 8 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,182,760.00 in company stock.

Percentage Held by Insiders

Only 0.39% of the stock of Insulet is held by insiders.

PODD Stock Analysis - Frequently Asked Questions

How have PODD shares performed this year?

Insulet's stock was trading at $261.07 at the beginning of the year. Since then, PODD shares have increased by 16.6% and is now trading at $304.39.
View the best growth stocks for 2025 here.

How were Insulet's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) posted its quarterly earnings results on Thursday, May, 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The company's quarterly revenue was up 28.8% compared to the same quarter last year.
Read the conference call transcript.

Who are Insulet's major shareholders?

Insulet's top institutional investors include Vanguard Group Inc. (12.32%), Baillie Gifford & Co. (3.20%), American Century Companies Inc. (1.64%) and Groupama Asset Managment (1.50%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, John W Kapples, Wayde D Mcmillan, Bret Christensen, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Wayne AI Frederick, Shacey Petrovic and Luciana Borio.
View institutional ownership trends.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/17/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:PODD
• CIK: 1145197
• Web: www.insulet.com
• Phone: (978) 600-7000
• Fax: 978-600-0120
• Employees: 3,900
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $321.00
• High Stock Price Target: $380.00
• Low Stock Price Target: $223.00
• Potential Upside/Downside: +5.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 18 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $5.56
• Trailing P/E Ratio: 54.75
• Forward P/E Ratio: 77.65
• P/E Growth: 2.73
• Net Income: $418.30 million
• Net Margins: 18.29%
• Pretax Margin: 13.34%
• Return on Equity: 22.25%
• Return on Assets: 8.29%

Debt

• Debt-to-Equity Ratio: 1.21
• Current Ratio: 4.47
• Quick Ratio: 3.63

Sales & Book Value

• Annual Sales: $2.07 billion
• Price / Sales: 10.34
• Cash Flow: $4.43 per share
• Price / Cash Flow: 68.66
• Book Value: $17.27 per share
• Price / Book: 17.63

Miscellaneous

• Outstanding Shares: 70,380,000
• Free Float: 70,101,000
• Market Cap: $21.42 billion
• Optionable: Optionable
• Beta: 1.37